<DOC>
	<DOCNO>NCT01416311</DOCNO>
	<brief_summary>To investigate safety efficacy actual use REVOLADE collect subject receive drug data specify number subject accumulate identify factor consider influence safety efficacy . &lt; Priority investigation item &gt; Thromboembolism</brief_summary>
	<brief_title>Drug Use Investigation REVOLADE ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<criteria>Subjects chronic idiopathic thrombocytopenic purpura</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>